<DOC>
	<DOCNO>NCT00338962</DOCNO>
	<brief_summary>The purpose study evaluate efficacy naltrexone combination SSRI reduce alcohol consumption alcoholic patient comorbid PTSD depression . We hypothesize combination naltrexone SSRI exhibit great decrease alcohol consumption see treatment SSRI alone , combination another class antidepressant naltrexone . We also hypothesize SSRI effective treat PTSD depressive symptom naltrexone well tolerate .</brief_summary>
	<brief_title>Naltrexone &amp; SSRI Alcoholics With Depression/PTSD</brief_title>
	<detailed_description>OBJECTIVE : Alcoholics current comorbid mental disorder constitute majority alcoholic clinical setting . Although two FDA approve medication treatment alcoholism ( naltrexone disulfiram ) , establish pharmacotherapies individual comorbid alcoholism psychiatric illness . Studies suggest class antidepressant know serotonin selective reuptake inhibitor ( SSRIs ) effective reduce alcohol use depressed individual . In addition , small open label study show SSRIs similar effect individual comorbid PTSD alcoholism . Preclinical study show combination serotonergic agent naltrexone effective either medication alone suppress alcohol intake . To address issue , conduct 13 week randomize clinical trial evaluate effect paroxetine , desipramine naltrexone reduce alcohol use alcohol dependent individual currently meet DSM-IV diagnosis Depressive Disorder PTSD . RESEARCH PLAN : One hundred twenty subject alcohol dependent patient comorbid PTSD Depressive Disorder recruit follow West Haven VA source : Substance Abuse Treatment program , PTSD clinic , Women 's clinic , clinical referral advertisement . These subject randomize double-blind fashion one four cell . We compare paroxetine versus desipramine naltrexone versus placebo . The antidepressant start low dose titrate upward fix schedule . The target dose 40mg paroxetine 200mg desipramine . Minimum dosage permit study retention 20mg paroxetine 150mg desipramine . Pharmacological treatment last 13 week . Psychosocial treatment involve medication compliance therapy , use Microelectric Event Monitoring ( MEMS ) bottle cap . The specific aim research compare relative effectiveness paroxetine versus desipramine naltrexone versus placebo reduce quantity frequency alcohol consumption . METHODOLOGY : The primary outcome measure major interest include : frequency quantity alcohol consumption , self-reported craving , self-reported psychiatric emotional distress , diagnostic assessment psychiatric symptom side effect . These outcome measure follow : self-assessments , Timeline Followback , Hamilton Depression anxiety scale , CAPS , ASI , Quality Life , breathalyzer test monthly liver function test .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Desipramine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>DSMIV diagnosis alcohol dependence current DSMIV depressive disorder PTSD recent episode heavy drinking outpatient , sober alcohol abused substance least 2 day randomization stable medication regiment least 2 week woman adequate method contraception current opioid dependence abuse history ( within last 3 month ) opioid dependence abuse pregnant history psychotic disorder current treatment antipsychotic medication medication think influence drink include : acamprosate , disulfiram , naltrexone , ondansetron , valproic acid tegretol current ( within lst 6 month ) use MAO inhibitor suicidal active ideation intent significant underlying medical condition history cardiac condition abnormality</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>SSRI</keyword>
	<keyword>treatment</keyword>
	<keyword>naltrexone</keyword>
	<keyword>alcohol dependence</keyword>
	<keyword>Desipramine</keyword>
	<keyword>depression</keyword>
	<keyword>PTSD</keyword>
</DOC>